Clinical Trial Update: Observational Study of Type 1 and Type 2 Diabetes Patients Having Switched From Human Premixes to NovoMix®30

View source ↗

Summary

This completed observational study evaluated diabetes patients (Type 1 and Type 2) who switched from human premixed insulin to NovoMix 30.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus
• Type 1 Diabetes Mellitus
• Type 2 Diabetes Mellitus

Drugs mentioned

• NovoMix 30 (insulin aspart protamine fixed-dose combination)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes, Diabetes Mellitus, Type 1 | Status: COMPLETED